gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

UDP glucuronosyltransferase 2 family, polypeptide B7

UGT2B7, UDP-glucuronosyltransferase 2B7
The protein encoded by this gene belongs to the UDP-glycosyltransferase (UGT) family. UGTs serve a major role in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This protein is localized in the microsome membrane, and has unique specificity for 3,4-catechol estrogens and estriol, suggesting that it may play an important role in regulating the level and activity of these potent estrogen metabolites. [provided by RefSeq, Sep 2011] (from NCBI)
Top mentioned proteins: UDP-glucuronosyltransferase, UGT, Glucuronosyltransferase, UGT1A1, ACID
Papers on UGT2B7
Oral morphine pharmacokinetic in obesity: the role of P-glycoprotein, MRP2, MRP3, UGT2B7 and CYP3A4 jejunal contents and obesity-associated biomarkers.
New
Decleves et al., In Mol Pharm, Feb 2016
OBJECTIVE: To study the influence of the jejunal expression levels of P-gp, MRP2, MRP3, UGT2B7, CYP3A4, the influence of the ABCB1 c.3435C>T polymorphism and of several obesity-associated biomarkers, on oral morphine and glucuronides pharmacokinetics in a population of morbid obese subjects.
The pharmacogenetics of opioid therapy in the management of postpartum pain: a systematic review.
New
Koren et al., Toronto, Canada. In Pharmacogenomics, Jan 2016
This systematic review reveals that CYP2D6, OPRM1 A118G, UGT2B7 C802T and ABCB1 G2677AT may contribute to postpartum analgesia or adverse events.
Characterization of 137 Genomic DNA Reference Materials for 28 Pharmacogenetic Genes: A GeT-RM Collaborative Project.
New
Kalman et al., Camden, United States. In J Mol Diagn, Jan 2016
To address this need, the Centers for Disease Control and Prevention-based Genetic Testing Reference Material Coordination Program, in collaboration with members of the pharmacogenetic testing community and the Coriell Cell Repositories, has characterized 137 genomic DNA samples for 28 genes commonly genotyped by pharmacogenetic testing assays (CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5, CYP4F2, DPYD, GSTM1, GSTP1, GSTT1, NAT1, NAT2, SLC15A2, SLC22A2, SLCO1B1, SLCO2B1, TPMT, UGT1A1, UGT2B7, UGT2B15, UGT2B17, and VKORC1).
Effects of UGT2B7 genetic polymorphisms on serum concentrations of valproic acid in Chinese epileptic children comedicated with lamotrigine.
New
Guo et al., Changchun, China. In Ther Drug Monit, Jan 2016
VPA is a substrate of uridine diphosphate glucuronosyltransferase 2B7 (UGT2B7).
Albumin's Influence on Carprofen Enantiomers-Hymecromone Interaction.
New
Wang et al., Xi'an, China. In Chirality, Jan 2016
In contrast, no significant difference was observed for the inhibition of (S)-carprofen on UGT2B7 activity in the absence or presence of 0.5% BSA in the incubation system.
Efavirenz pharmacogenetics in a cohort of Italian patients.
New
D'Avolio et al., Torino, Italy. In Int J Antimicrob Agents, Jan 2016
Whole blood was used to identify SNPs in ABCB1, MRP2, CYP2B6, CYP2A6, UGT2B7, NR1I2 (PXR), NR1I3 (CAR) and HNF4α by real-time PCR.
Pharmacogenetics of drug-metabolizing enzymes in US Hispanics.
Review
New
Ruaño et al., In Drug Metabol Personal Ther, Jun 2015
A higher prevalence of CYP2C9*3, CYP2C19*4, and UGT2B7 IVS1+985 A>G was observed in US Hispanic vs. non-Hispanic populations.
Pharmacogenetics of CYP2B6, CYP2A6 and UGT2B7 in HIV treatment in African populations: focus on efavirenz and nevirapine.
Review
New
Pepper et al., Pretoria, South Africa. In Drug Metab Rev, May 2015
This review aims to investigate ethnic variation of CYP2B6, CYP2A6 and UGT2B7, and to understand the pharmacogenetic relevance when comparing frequencies in African populations to other populations worldwide.
An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS Patients.
Dandara et al., Cape Town, South Africa. In Front Genet, 2014
The drug metabolizing enzyme (DME), CYP2B6, is primarily responsible for EFV metabolism with minor contributions by CYP1A2, CYP2A6, CYP3A4, CYP3A5, and UGT2B7.
In Vitro Metabolic Pathways of the New Anti-Diabetic Drug Evogliptin in Human Liver Preparations.
Lee et al., Puch'ŏn, South Korea. In Molecules, 2014
Glucuronidation of 4(S)-hydroxy-evogliptin (M2) to 4(S)-hydroxyevogliptin glucuronide (M4) was catalyzed by the enzymes UGT2B4 and UGT2B7.
Effect of an ethanol extract of Descurainia sophia seeds on Phase I and II drug metabolizing enzymes and P-glycoprotein activity in vitro.
Kim et al., Taejŏn, South Korea. In Bmc Complement Altern Med, 2014
Other Phase I (CYP2C8, CYP2D6, and CYP3A4) and Phase II (UGT1A1 and UGT2B7) enzymes as well as P-gp were weakly or negligibly affected by EEDS with concentrations up to 500 μg/mL.
Effects of mitragynine and 7-hydroxymitragynine (the alkaloids of Mitragyna speciosa Korth) on 4-methylumbelliferone glucuronidation in rat and human liver microsomes and recombinant human uridine 5'-diphospho-glucuronosyltransferase isoforms.
Ismail et al., George Town, Malaysia. In Pharmacognosy Res, 2014
OBJECTIVE: The objective was to evaluate the inhibitory potentials of mitragynine, 7-hydroxymitragynine, ketamine and buprenorphine, respectively on 4-methylumbelliferone (4-MU) glucuronidation in rat liver microsomes, human liver microsomes and recombinant human UGT1A1 and UGT2B7 isoforms.
Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update.
Review
Tett et al., Brisbane, Australia. In Arch Toxicol, 2014
Genetic variants within genes involved in MPA metabolism (UGT1A9, UGT1A8, UGT2B7), cellular transportation (SLCOB1, SLCO1B3, ABCC2) and targets (IMPDH) have been reported to effect MPA pharmacokinetics and/or response in some studies; however, larger studies across different ethnic groups that take into account genetic linkage and drug interactions that can alter a patient's phenotype are needed before any clinical recommendations based on patient genotype can be formulated.
Genetic basis of drug-induced liver injury: present and future.
Review
Aithal et al., Newcastle upon Tyne, United Kingdom. In Semin Liver Dis, 2014
Though the associations with non-HLA genes have been less well replicated than the HLA associations, there is increasing evidence that drug metabolism genes such as NAT2 and UGT2B7 contribute to some forms of DILI.
Pharmacogenetic potential biomarkers for carbamazepine adverse drug reactions and clinical response.
Review
López et al., In Drug Metabol Drug Interact, 2013
On the other hand, in order to explain the differences in the clinical response to CBZ, genetic polymorphisms in phase I (CYP3A4, CYP3A5 and EPHX1) and phase II (UGT2B7) metabolising enzymes have been assessed; additionally, the influence of transporters (ABCB1 and ABCC2), receptors (PXR) and other drug targets (voltage- gated Na+ channels) in CBZ clinical response has been evaluated.
Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects.
GeneRIF
Somogyi et al., Adelaide, Australia. In Br J Clin Pharmacol, 2012
Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo
Human UDP-glucuronosyltransferase isoforms involved in haloperidol glucuronidation and quantitative estimation of their contribution.
GeneRIF
Yokoi et al., Kanazawa, Japan. In Drug Metab Dispos, 2012
Data suggest that UGT2B7 is the predominant activity in liver microsomes for haloperidol O-glucuronidation (in both human and rat).
Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization.
GeneRIF
Liou et al., Taiwan. In Pharmacogenomics, 2012
the present study revealed that EPHX1, UGT2B7 and SCN1A genetic polymorphisms simultaneously modulated the CBZ maintenance doses and CDRs(concentration-dose ratios)
Bovine serum albumin decreases Km values of human UDP-glucuronosyltransferases 1A9 and 2B7 and increases Vmax values of UGT1A9.
GeneRIF
Finel et al., Helsinki, Finland. In Drug Metab Dispos, 2011
In the case of UGT2B7, our results agree with the previously described effect of BSA, namely lowering the K(m) value without a large effect on the enzyme's V(max) value.
Transcriptional diversity at the UGT2B7 locus is dictated by extensive pre-mRNA splicing mechanisms that give rise to multiple mRNA splice variants.
GeneRIF
Guillemette et al., Québec, Canada. In Pharmacogenet Genomics, 2011
these findings point toward a significant variability in structure, abundance, and tissue-specific UGT2B7 transcriptome, in addition to novel functions for UGT2B7-derived proteins
share on facebooktweetadd +1mail to friends